CDK-IN-14

CDK-IN-14 (B34) is a CDK2 inhibitor (IC50=0.097 μM) with anti-hepatocellular carcinoma activity. CDK-IN-14 blocks the cell cycle of HepG-2 cancer cells through a caspase-mediated mechanism and induces apoptosis[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; Caspase; CDK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cdk-in-14-1.html

Smiles

COC1=C(OC)C=C(N=C(NC2=CC=C(OCC3=CC(F)=CC=C3)C(Cl)=C2)N=C4NCC5=CC=CC=C5)C4=C1

Molecular Formula

C30H26ClFN4O3

Molecular Weight

545.00

References & Citations

[1]Venkatesan G, et al. Design, synthesis, molecular docking, and evaluation of sulfonyl quinazoline analogues as promising liver cancer drugs[J]. Bioorganic Chemistry, 2024: 107777.